"Treating Triple-Class Refractory Myeloma With Ajai Chari, MD" - Sarah Williams
Ajai Chari, MD, associate professor, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai discusses the importance of STORM's results regarding selinexor/dexamethasone and shares his perspective on other agents that are in development for triple-class refractory multiple myeloma. According to Dr. Chari, “The first point to make is that this is a very hard-to-treat population. Triple-class refractory means that patients are refractory to the three major classes of drugs we use in myeloma: proteasome inhibitors, immunomodulatory drugs, and the CD38 antibody.” He added, “Fortunately, there is so much work being done in myeloma, thanks to a lot of collaborations between academia, pharmaceutical companies, nonprofits, and the FDA through organizations such as the Multiple Myeloma Research Consortium. I think that this brain trust with a lot of stakeholders is the reason behind a lot of drug development in this space. As I alluded to, I think that the next big target will probably be anti-BCMA therapies.”
— Ajai Chari, MD, Director, Clinical Research in the Multiple Myeloma Program, Associate Director, Clinical Research, Mount Sinai Cancer Clinical Trials Office, Associate Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai
Unprecedented Therapy Found Effective for Blood Cancer Patients With No Treatment Options
Aug 22, 2019 View All Press Releases